• Delic Corp is a leading psychedelic wellness platform with a business network which includes psychedelic wellness clinics, psilocybin research facilities, a famed psychedelic wellness event, and dedicated media and e-commerce platforms
• Delic’s CEO, Matt Stang recently joined the Gamechangers LIVE podcast to share his perspective on the development of the psychedelic industry along with Delic’s commercial evolution

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic wellness platform committed to bringing science-backed benefits to its many stakeholders, has long been known for its role as a trailblazer of new medicines and treatments in the current environment. Its goal is to improve access to health benefits and reframe the conversation on psychedelics.

The company has sought to achieve its goals through its string of related businesses, which include Ketamine Wellness Centers, the largest chain of psychedelic wellness clinics in the country; Delic Labs, the sole entity currently licensed by Health Canada to focus exclusively on research and development of psilocybin vaporization technology; Meet Delic, the company’s eponymous psychedelic wellness event; as well as media and e-commerce platforms, Reality Sandwich, and Delic Radio.

Matt Stang, Co-founder and CEO of Delic Corp recently joined the Gamechangers LIVE podcast to share his perspective on the psychedelic industry and share insights into the evolution of Delic Corp into its current form (https://ibn.fm/ab0yt).

During the interview, Stang elaborated on his colorful background within the alternative drugs sector, a journey which began when he interned at High Times, a leading counterculture publication which would go on to become the voice for the cannabis industry.

“I started off as an intern. It’s one of those wonderful stories. I graduated from college and wrote a senior thesis on legalization of marijuana. My thesis was that, with the terrorist attacks of 9/11, we could bring conservatives on board to legalization with a ‘tax and regulate’ strategy,” Stang said. “I submitted it to a friend who was friends with the General Counsel. He read it, loved it, and asked me to come in and intern. So, a week after I graduated, I got an internship at High Times and worked my way up…”

Stang would ultimately go on to become the owner and operator of High Times, a position which he leveraged in his attempt to play a role in legalizing cannabis usage across several different states.

“Now, two-thirds or more of the country live under some form of cannabis legalization… The world is changing in front of our eyes. I think the same thing is happening with psychedelics, but on a greater level and federally legal, because you have the FDA reviewing favorable clinical data for multiple psychedelics right now,” he continued.

The movement to decriminalize psilocybin, the key active ingredient within psychedelic drugs, kicked off in earnest a few years ago, with Denver, Colorado becoming the first city to decriminalize psilocybin in May 2019. The cities of Oakland and Santa Cruz, California, followed suit and decriminalized psilocybin in June 2019 and January 2020, respectively (https://ibn.fm/lucZB). However, the movement has gained further momentum in recent times, with the likes of actor Will Smith commenting on his use of ayahuasca (https://ibn.fm/6vlWC), and musician Lil Nas X saying he couldn’t have written the number one album of the year without gaining inspiration from a full-day mushroom trip alongside his producers (https://ibn.fm/5N3Zs).

During the podcast, Stang also went on to elaborate on the beneficial nature of psychedelic drugs and its ability to effectively supplant traditional benzodiazepines.

“You’ve got tons of people stuck on Xanax or Percocet or all of these ‘maintenance’ drugs that don’t actually change you at all. You take them every day and, for the four to six hours that they’re active, you feel better. When they wear off, you feel worse,” Stang added. “With our internal data, the ketamine that we utilize is having somewhere between a 70-80% efficacy rate, meaning people are curative or better from using it for a certain period of time. With MDMA, they had a 77% rate. With psilocybin, it was closer to 80%.

The full podcast interview with Delic Corp Co-Founder and CEO, Matt Stang can be found here: https://youtu.be/QIF12RiuAOQ

For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. 

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.